Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Baricitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 known ✓ | P23458 | 20/20 | 1.00 |
| ▸ | JAK2 known ✓ | O60674 | 19/20 | 1.00 |
| ▸ | JAK3 | P52333 | 15/20 | 1.00 |
| ▸ | TYK2 | P29597 | 3/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 1/20 | 1.00 |
| ▸ | ULK1 | O75385 | 1/20 | 1.00 |
| ▸ | PRKCB | P05771 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | PRKCA | P17252 | 1/20 | 1.00 |
| ▸ | PRKACA | P17612 | 1/20 | 1.00 |
| ▸ | MARK3 | P27448 | 1/20 | 1.00 |
| ▸ | STAT3 | P40763 | 1/20 | 1.00 |
| ▸ | CLK1 | P49759 | 1/20 | 1.00 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 1/20 | 1.00 |
| ▸ | MAP3K1 | Q13233 | 1/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 1/20 | 1.00 |
| ▸ | TNK1 | Q13470 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Baricitinib SCHEMBL29349824 | 1.00 | JAK1 (1.00) | JAK1JAK2JAK3TYK2CIT | |
| Baricitinib SCHEMBL20135561 | 0.99 | JAK1 (0.98) | JAK1JAK2JAK3TYK2CIT | |
| Baricitinib SCHEMBL20135563 | 0.99 | JAK1 (0.98) | JAK1JAK2JAK3TYK2CIT | |
| Baricitinib SCHEMBL20135659 | 0.97 | JAK1 (0.95) | JAK1JAK2JAK3TYK2CIT | |
| Baricitinib SCHEMBL20135562 | 0.97 | JAK1 (0.95) | JAK1JAK2JAK3TYK2CIT | |
| Baricitinib SCHEMBL20135649 | 0.96 | JAK1 (0.93) | JAK1JAK2JAK3TYK2CIT | |
| Baricitinib SCHEMBL20135651 | 0.96 | JAK1 (0.93) | JAK1JAK2JAK3TYK2CIT | |
| Baricitinib SCHEMBL871037 | 0.96 | JAK1 (0.92) | JAK1JAK2JAK3TYK2CIT | |
| Baricitinib SCHEMBL1396340 | 0.96 | JAK1 (0.92) | JAK1JAK2JAK3TYK2CIT | |
| SCHEMBL872210 | 0.95 | JAK1 (0.90) | JAK1JAK2JAK3TYK2CIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 387 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117462554-A | Application of barytinib in preparation of chronic non-bacterial mastitis treatment drugs | 浙江大学医学院附属第一医院 | 2024-01-30 | — | — | CN | claimed |
| US-20200093825-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | INCYTE CORPORATION | 2020-03-26 | — | — | US | claimed |
| EP-3321267-A1 | CRYSTALLINE FORMS OF 2-[1-ETHYLSULFONYL-3-[7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PYRAZOL-1-YL]AZETIDIN-3-YL]ACETONITRILE SALTS AND PREPARATION THEREOF | Zentiva K.S. (CZ) | 2018-05-16 | — | — | EP | claimed |
| EP-2288610-B1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE HOLDINGS CORP (US) | 2016-08-31 | — | — | EP | claimed |
| EP-3042655-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | Incyte Holdings Corporation (US) | 2016-07-13 | — | — | EP | claimed |
| US-20140377221-A1 | BIOMARKERS AND COMBINATION THERAPIES USING ONCOLYTIC VIRUS AND IMMUNOMODULATION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-12-25 | — | — | US | claimed |
| EP-2806883-A1 | BIOMARKERS AND COMBINATION THERAPIES USING ONCOLYTIC VIRUS AND IMMUNOMODULATION | Dnatrix Inc. (US) | 2014-12-03 | — | — | EP | claimed |
| WO-2013173506-A2 | METHOD OF TREATING MUSCULAR DEGRADATION | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | WO | claimed |
| US-20130310340-A1 | METHOD OF TREATING MUSCULAR DEGRADATION | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | US | claimed |
| WO-2013112942-A1 | BIOMARKERS AND COMBINATION THERAPIES USING ONCOLYTIC VIRUS AND IMMUNOMODULATION | DNA TRIX, INC. (US) | 2013-08-01 | — | — | WO | claimed |
| US-8420629-B2 | Azetidine and cyclobutane derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2013-04-16 | — | — | US | claimed |
| US-8158616-B2 | Azetidine and cyclobutane derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2012-04-17 | — | — | US | claimed |
| US-20120077798-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2012-03-29 | — | — | US | claimed |
| EP-2288610-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | Incyte Corporation (US) | 2011-03-02 | — | — | EP | claimed |
| US-20100113416-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | INCYTE CORPORATION | 2010-05-06 | — | — | US | claimed |
| WO-2009114512-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2009-09-17 | — | — | WO | claimed |
| US-20090233903-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2009-09-17 | — | — | US | claimed |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| WO-2009114512-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2009-09-17 | — | — | WO | disclosed |
| US-20090233903-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310340-A1 | METHOD OF TREATING MUSCULAR DEGRADATION | PYGM, CKMT1A; CKMT1B, SMN1; SMN2 | JAK1 4796/4885JAK2 4729/4885JAK3 4792/4885 |
| US-20100113416-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | JAK1, JAK3, JAK2 | JAK1 1/4885JAK2 3/4885JAK3 2/4885 |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | JAK2, TP53, CDKN1A | JAK1 8/4885JAK2 1/4885JAK3 91/4885 |
| US-20200093825-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | JAK1, JAK3, JAK2 | JAK1 1/4885JAK2 3/4885JAK3 2/4885 |
| US-20090233903-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | JAK1 1/4885JAK2 2/4885JAK3 3/4885 |
| US-20120077798-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | JAK1 1/4885JAK2 2/4885JAK3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.